24/08/2026 Johnson & Johnson received FDA approval for nipocalimab for the treatment of warm autoimmune hemolytic anemia US FDA granted Orphan Drug Designation to gamgertamig for the treatment of pemphigus Johnson & Johnson received FDA approval for nipocalimab for the treatment of warm autoimmune hemolytic anemia (Ref) Johnson & Johnson announced that the US FDA approved IMAAVY® (nipocalimab-aahu; FcRn blocker) for adults and paediatric patients 12 years of age and older wit

04/06/2026 Gilead Sciences and Lakefront completed the acquisition of Ouro Medicines to further expand inflammation pipeline Gilead Sciences and Lakefront completed the acquisition of Ouro Medicines to further expand inflammation pipeline (Ref) Gilead Sciences and Lakefront Biotherapeutics announced the successful completion of the previously announced acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases. The acquisition added gamgertamig